Modified FOLFOX Regimen for Colorectal Cancer
Author Information
Author(s): Goldstein D, Mitchell P, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Clarke S
Primary Institution: Prince of Wales Hospital, Randwick, Sydney, Australia
Hypothesis
Can a modified FOLFOX regimen improve patient convenience and maintain efficacy in untreated metastatic colorectal cancer patients?
Conclusion
The modified FOLFOX regimen improved patient convenience without compromising efficacy or toxicity.
Supporting Evidence
- 52% of patients had a complete or partial response to treatment.
- The median progression-free survival was 8.2 months.
- The median overall survival was 18.7 months.
- 36% of patients experienced grade 3/4 neutropenia.
- 21% of patients experienced grade 3 neurotoxicity.
Takeaway
Doctors tested a new way to give chemotherapy to people with colon cancer, making it easier for them to get treatment while still helping them get better.
Methodology
Patients received a modified FOLFOX regimen as outpatients, with treatment cycles every two weeks until disease progression or unacceptable toxicity.
Limitations
The study was limited to a small sample size and specific patient demographics.
Participant Demographics
Median age was 61 years, with 59% aged 60 or older and 97% Caucasian.
Statistical Information
Confidence Interval
95% CI 38–65% for response rate; 95% CI 7.1–9.9 months for PFS; 95% CI 14.0–23.4 months for OS.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website